Admin
Categories
- 3922 – lorlatinib by Pfizer
- alectinib – Alecensa from Chugai – Roche – GenenTech
- Anaplastic Large-Cell Lymphomas
- AP26113 – brigatinib from Ariad
- ASP3026 from Astellas
- Brain metastases
- CEP-37440
- ceritinib – Zykadia from Novartis
- crizotinib – Xalkori from Pfizer
- Experiences
- Glioblastomas
- Imunotherapies
- JH-VIII-157-02
- Lung cancer
- Neuroblastomas
- NMS-E628
- PLB1003 – Beijing Pearl Biotechnology
- Potential Treatments
- Regulatory applications & approvals
- Research
- Resistance to treatment
- RXDX-101 – entrectinib – by Ignyta
- Side Effects
- TPX-0005: TP Therapeutics
- TSR-011 from Tesaro
- Uncategorized
- X-396 – ensartinib from Xcovrery
Category Archives: X-396 – ensartinib from Xcovrery
List of 9 ALK Inhibitors
List of 9 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Novartis – Ceritinib Pfizer – Crizotinib FDA Breakthrough Status Chugai – Alectinib (filed NDA in Japan) Ongoing trials Ariad AP26113 Nerviano NMS-E628. (Licensed by … Continue reading
Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery
Leave a comment
Clinical trial results to be announced at ASCO 2014 (5/30 to 6/3)
Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). (Abstract 8047) Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. … Continue reading
List of drugs in clinical trials
List of 10 ALK inhibitor drugs currently (or soon to be) in clinical trials: Ariad AP26113 Astellas ASP-3026 Chugai Alectinib (filed NDA in Japan) Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101) Novartis LDK-378 Pfizer Crizotinib (FDA approved but several … Continue reading
Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, NMS-E628, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery
Leave a comment